Drugs & Treatments

//Drugs & Treatments

Pamorelin (Trelstar) Now Available in the Philippines

Pamorelin (Trelstar® )is going to become available in the Philippines. Pamorelin, and Decapeptyl® will be made available to urologists and oncologists who treat men with advanced prostate cancer. It will be available in one, three and six month formulations. Pamorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It is designed to chemically [...]

ASCO Releases A Statement of Principles Balancing Patient Access to Opioids with Curbing Drug Abuse

The American Association of Clinical Oncology (ASCO) released a very important new policy statement that details their position surrounding the prescribing of  opioids to cancer patients. This issue has taken the forefront of controversy as our society increasingly becomes concerned about the overuse of prescription opioids, sometimes leaving out the very specific needs of cancer [...]

Abiraterone And Enzalutamide Effect Cognitive Impairment and Depression in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Speaking with men who have taken abiraterone (Zytiga, ABI) and enzalutamide (Xtandi, ENZA), at Malecare we sometimes hear reports of both cognitive and mood changes brought on by these two drugs. Evaluating these two problematic side effects researchers have confirmed our experience, both of these drugs can cause these symptoms and that more men reported [...]

How To Have A Firmagon Injection And Minimized The Side Effects

Three of the participants on the Malecare Health Unlocked Advanced Prostate Cancer Online Support Group have been sharing their personal experiences and recommendations on how to best get a Firmagon injection. It is clear that how the injection is given has a direct effect on he pain and inflammation a man will experience from the [...]

A Prospective Evaluation Of The Health Related Quality of Life In Men Receiving Primary and Secondary Treatment for Prostate Cancer

Men with both high risk and intermediate risk prostate cancer will receive primary treatment and many also receive a second line of treatment. In a study that was designed to assess the impact of receiving both first and second line treatment on a man’s Health Related Quality of Life (HRQoL), researchers determined that men who [...]

Understanding the Reality of the Side Effects from Early Chemotherapy

Ever since the research showing that men who are newly diagnosed with very aggressive prostate cancer have a significant life extension advantage if they move immediately to chemotherapy (with docetaxel) along with hormone therapy (ADT) there has been, what I can only describe as a paradigm shift in the clinical care of men with metastatic [...]

Understanding the Complexity of Prostate Cancer Drug Names – Cutting Through The Confusion

As drugs are developed they are given many different names, but the drug (or treatment) is the same despite its name. For us laymen, multiple names for the same drug is confusing. So, why are there so many different names for the same thing? Drugs usually have three different names; A chemical name that relates [...]

An Independent Prognostic Tool For Men With Metastatic Castrate Resistant Prostate Cancer Taking The Newer Drugs

We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]

Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial

The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]

Short Term Androgen Therapy Might Be Better For More Aggressive Gleason Grade Prostate Cancer

In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]